{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT04743791",
            "orgStudyIdInfo": {
                "id": "STUDY20020131"
            },
            "organization": {
                "fullName": "University of Pittsburgh",
                "class": "OTHER"
            },
            "briefTitle": "Measuring the Effect of Dupilumab Treatment on Mucociliary Clearance (MCC) in Subjects With Moderate to Severe Asthma",
            "officialTitle": "A Randomized, Placebo-controlled, Parallel Group Study Designed to Assess the Change in Mucociliary Clearance After 12 Weeks of Treatment With Dupilumab in Patients With Moderate to Severe Asthma",
            "therapeuticArea": [
                "Respiratory"
            ],
            "study": "measuring-the-effect-of-dupilumab-treatment-on-mucociliary-clearance-mcc-in-subjects-with-moderate-to-severe-asthma"
        },
        "statusModule": {
            "statusVerifiedDate": "2023-10",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2022-10-17",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2025-04",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2025-09",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2021-02-03",
            "studyFirstSubmitQcDate": "2021-02-03",
            "studyFirstPostDateStruct": {
                "date": "2021-02-08",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2023-10-04",
            "lastUpdatePostDateStruct": {
                "date": "2023-10-06",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR_INVESTIGATOR",
                "investigatorFullName": "Sally E. Wenzel MD",
                "investigatorTitle": "Professor",
                "investigatorAffiliation": "University of Pittsburgh"
            },
            "leadSponsor": {
                "name": "Sally E. Wenzel MD",
                "class": "OTHER"
            }
        },
        "oversightModule": {
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false,
            "isUsExport": false
        },
        "descriptionModule": {
            "briefSummary": "Single center, randomized, placebo- controlled study to assess change in mucociliary clearance of moderate to severe asthma patients after treatment with dupilumab or placebo."
        },
        "conditionsModule": {
            "conditions": [
                "Asthma"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE4"
            ],
            "designInfo": {
                "allocation": "RANDOMIZED",
                "interventionModel": "PARALLEL",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "QUADRUPLE",
                    "maskingDescription": "Dupilumab and placebo will be provided in identically matched 1.14 mL pre-filled syringes. To protect the blind, each treatment kit of 1.14 mL (dupilumab / placebo) glass pre-filled syringes will be prepared such that the treatments (dupilumab and its matching placebo) are identical and indistinguishable and will be labeled with a treatment kit number. The randomized treatment kit number list will be generated by Sanofi Regeneron",
                    "whoMasked": [
                        "PARTICIPANT",
                        "CARE_PROVIDER",
                        "INVESTIGATOR",
                        "OUTCOMES_ASSESSOR"
                    ]
                }
            },
            "enrollmentInfo": {
                "count": 30,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Dupilumab",
                    "type": "ACTIVE_COMPARATOR",
                    "description": "Two injections of Dupilumab will be administered at Week 0/Visit 3 as a loading dose. Subsequently one injection of Dupilumab will be given every 2 weeks \u00b1 3 days at home by the patient. The doses of investigational product must be separated by \u226511 days to avoid an overdose.",
                    "interventionNames": [
                        "Drug: Dupilumab"
                    ]
                },
                {
                    "label": "Placebo",
                    "type": "PLACEBO_COMPARATOR",
                    "description": "Two injections of placebo will be administered at Week 0/Visit 3 as a loading dose. Subsequently one injection of placebo will be given every 2 weeks \u00b1 3 days at home by the patient. The doses must be separated by \u226511 day.",
                    "interventionNames": [
                        "Other: Placebo"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "Dupilumab",
                    "description": "Dupilumab is supplied as a sterile aqueous solution for SC injection at the concentration of 175 mg/mL in glass pre-filled syringe to deliver 200 mg in 1.14mL.",
                    "armGroupLabels": [
                        "Dupilumab"
                    ]
                },
                {
                    "type": "OTHER",
                    "name": "Placebo",
                    "description": "Sterile placebo for dupilumab will be provided in identically matched glass pre-filled syringe to deliver 200 mg in 1.14mL, which will match dupilumab 200 mg (1.14mL).",
                    "armGroupLabels": [
                        "Placebo"
                    ],
                    "otherNames": [
                        "Sucrose"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Change in mucociliary clearance (MCC) rate",
                    "description": "MCC is measured using an aerosol-based nuclear imaging technique",
                    "timeFrame": "Measured at 12 weeks after the start of treatment"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Change in FEV1% predicted",
                    "description": "Assessed using spirometry after bronchodilator administration.",
                    "timeFrame": "Measured from baseline to 12 weeks after start of treatment"
                },
                {
                    "measure": "Change in ACT score",
                    "description": "Measured via the Asthma Control Test questionnaire. Scores range from 5 (poor control of asthma) to 25 (complete control of asthma).",
                    "timeFrame": "Measured from baseline to 12 weeks after start of treatment"
                },
                {
                    "measure": "Change in sputum eosinophils and T2 gene mean",
                    "description": "Measured via sputum induction to obtain airway cells and fluid from patients.",
                    "timeFrame": "Measured from baseline to 12 weeks after start of treatment"
                },
                {
                    "measure": "Change in mucus plugging score by CT",
                    "description": "Radiologists will visually assess the presence or absence of mucus plugging in segmental airways and will provide a mucus plugging score",
                    "timeFrame": "Measured from baseline to 12 weeks after start of treatment"
                },
                {
                    "measure": "Whole lung MCC90, AAC90",
                    "description": "Measured via mucociliary clearance imaging",
                    "timeFrame": "Measured from baseline to 12 weeks after start of treatment"
                },
                {
                    "measure": "Peripheral and central lung MCC90, MCC240, AAC90",
                    "description": "Measured via mucociliary clearance imaging",
                    "timeFrame": "Measured from baseline to 12 weeks after start of treatment"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n* Moderate - Severe Th2 (Type 2) High asthma, as defined by Forced Expiratory Volume in one second (FEV1) \\<90% predicted, on medium to high dose inhaled corticosteroids (ICS) with or without a second controller\n* Age \\> 18\n* Inhaled steroid doses of 500micrograms (mcg) per day or more (Fluticasone equivalent)\n* Reversibility \\>/= 12% at screening or within the past 2 years, or a positive methacholine challenge test within the past 2 years, or a positive methacholine challenge during screening\n* FEV1/Forced Vital Capacity (FVC)\\<75%\n* Blood Eosinophils (EOS) \\>300 cells per mm3\n* Exhaled Nitric Oxide (FeNO) \\>25 parts per billion (ppb)\n* Asthma Control Test (ACT) score \\<20\n\nExclusion Criteria:\n\n* Pregnant, nursing, or unwilling to test for pregnancy\n* Current smoker or \\>10 pack year smoking history\n* Body Mass Index (BMI)\\>37\n* Respiratory infection in the last 30 days\n* Use of antibiotics or oral prednisone in the last 30 days\n* Current or previous use of dupilumab\n* Current or recent use of anti-IL-5 therapies\n* Any other criteria that place the subject at unnecessary risk\n* Diagnosis of other lung diseases including Chronic Obstructive Pulmonary Disease (COPD)\n* History of non-skin cell cancer in the last 5 years\n* Drug or alcohol addiction in the last 5 years\n* Any other uncontrolled disease",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "John Moore",
                    "role": "CONTACT",
                    "phone": "412-648-6726",
                    "email": "mooreja6@upmc.edu"
                }
            ],
            "locations": [
                {
                    "facility": "The University of Pittsburgh Asthma Institute at UPMC",
                    "status": "RECRUITING",
                    "city": "Pittsburgh",
                    "state": "Pennsylvania",
                    "zip": "15213",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Sally Wenzel, MD",
                            "role": "CONTACT",
                            "phone": "412-647-9955",
                            "email": "swenzel@pitt.edu"
                        },
                        {
                            "name": "John Moore",
                            "role": "CONTACT",
                            "phone": "412-648-6726",
                            "email": "mooreja6@upmc.edu"
                        }
                    ],
                    "geoPoint": {
                        "lat": 40.44062,
                        "lon": -79.99589
                    }
                }
            ]
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000001249",
                    "term": "Asthma"
                }
            ],
            "ancestors": [
                {
                    "id": "D000001982",
                    "term": "Bronchial Diseases"
                },
                {
                    "id": "D000012140",
                    "term": "Respiratory Tract Diseases"
                },
                {
                    "id": "D000008173",
                    "term": "Lung Diseases, Obstructive"
                },
                {
                    "id": "D000008171",
                    "term": "Lung Diseases"
                },
                {
                    "id": "D000012130",
                    "term": "Respiratory Hypersensitivity"
                },
                {
                    "id": "D000006969",
                    "term": "Hypersensitivity, Immediate"
                },
                {
                    "id": "D000006967",
                    "term": "Hypersensitivity"
                },
                {
                    "id": "D000007154",
                    "term": "Immune System Diseases"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M4556",
                    "name": "Asthma",
                    "asFound": "Asthma",
                    "relevance": "HIGH"
                },
                {
                    "id": "M5258",
                    "name": "Bronchial Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M14977",
                    "name": "Respiratory Tract Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M11168",
                    "name": "Lung Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M11170",
                    "name": "Lung Diseases, Obstructive",
                    "relevance": "LOW"
                },
                {
                    "id": "M10018",
                    "name": "Hypersensitivity",
                    "relevance": "LOW"
                },
                {
                    "id": "M14967",
                    "name": "Respiratory Hypersensitivity",
                    "relevance": "LOW"
                },
                {
                    "id": "M10020",
                    "name": "Hypersensitivity, Immediate",
                    "relevance": "LOW"
                },
                {
                    "id": "M10200",
                    "name": "Immune System Diseases",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC08",
                    "name": "Respiratory Tract (Lung and Bronchial) Diseases"
                },
                {
                    "abbrev": "BC20",
                    "name": "Immune System Diseases"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                }
            ]
        },
        "interventionBrowseModule": {
            "browseLeaves": [
                {
                    "id": "M21860",
                    "name": "Pharmaceutical Solutions",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "PhSol",
                    "name": "Pharmaceutical Solutions"
                },
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                }
            ]
        }
    },
    "hasResults": false
}